At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 232 enrolled
Drug / intervention
Maxigesic® IVdrug
Likely dose
Maxigesic® IV 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Multiple-Dose, Single-Arm Exposure Study of Maxigesic® IV in Patients With Acute Pain Following Orthopedic, General or Plastic Surgery
In Brief
A Phase 3 clinical trial evaluating Maxigesic® IV for Postoperative Pain. Completed, enrolled 232 participants across 4 sites in 2 countries.
Detailed Summary
The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Pain
CountriesNew Zealand, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartJul 2019
Primary CompletionJun 2020
Study CompletionJul 2020
TodayJul 2026
First PostedJul 2, 2019
Enrollment StartJul 22, 2019
Primary CompletionJun 30, 2020
Study CompletionJul 7, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7 years ago
Interventions
Maxigesic® IVdrug
acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion